Evidence map›Paper›PMID 31662322›Full record

ReviewAnnals of the rheumatic diseases2020

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019.

Kevin L Winthrop, Michael E Weinblatt, Joan Bathon, Gerd R Burmester, Philip J Mease, Leslie Crofford, Vivian Bykerk, Maxime Dougados, James Todd Rosenbaum, Xavier Mariette and 7 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of the rheumatic diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Mesenchymal Stem Cells-Involved Strategies for Rheumatoid Arthritis Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Kevin L WinthropOregon Health Sciences University, Portland, Oregon, USA winthrop@ohsu.edu.ORCID 0000-0002-3892-6947
Michael E WeinblattBrigham and Womens Hospital, Boston, Massachusetts, USA.
Joan BathonColumbia University, College of Physicians & Surgeons, New York City, New York, USA.
Gerd R BurmesterCharité University Hospital, Berlin, Germany.
Philip J MeaseSwedish Medical Center, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-6620-0457
Leslie CroffordVanderbilt University, Nashville, Tennessee, USA.
Vivian BykerkHospital for Special Surgery, New York City, New York, USA.
Maxime DougadosHôpital Cochin, Paris, France.
James Todd RosenbaumOregon Health Sciences University, Portland, Oregon, USA.
Xavier MarietteParis-Sud University, APHP Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin Bicêtre, France.
Joachim SieperDepartment of Gastroenterology, Infectious Diseases and Rheumatology, Campus Benjamin Franklin, Charité, Berlin, Germany.
Fritz MelchersMax Planck Institute for Infection Biology, Berlin, Germany.
Bruce N CronsteinNYU School of Medicine, New York City, New York, USA.
Ferry C BreedveldLeiden University Medical Center, Leiden, The Netherlands.
Joachim KaldenUniversity of Erlangen, Erlangen, Germany.
Josef S SmolenDivision of Rheumatology, Department of Medicine 3, Medical University of, Vienna, Vienna, Austria.
Daniel FurstSwedish Medical Center, University of Washington, Seattle, Washington, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo detail the greatest areas of unmet scientific and clinical needs in rheumatology.

methodsThe 21st annual international Advances in Targeted Therapies meeting brought together more than 100 leading basic scientists and clinical researchers in rheumatology, immunology, epidemiology, molecular biology and other specialties. During the meeting, breakout sessions were convened, consisting of 5 disease-specific groups with 20-30 experts assigned to each group based on expertise. Specific groups included: rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, systemic lupus erythematosus and other systemic autoimmune rheumatic diseases. In each group, experts were asked to identify unmet clinical and translational research needs in general and then to prioritise and detail the most important specific needs within each disease area.

resultsOverarching themes across all disease states included the need to innovate clinical trial design with emphasis on studying patients with refractory disease, the development of trials that take into account disease endotypes and patients with overlapping inflammatory diseases, the need to better understand the prevalence and incidence of inflammatory diseases in developing regions of the world and ultimately to develop therapies that can cure inflammatory autoimmune diseases.

conclusionsUnmet needs for new therapies and trial designs, particularly for those with treatment refractory disease, remain a top priority in rheumatology.

Indexed as

Clinical Trials as TopicResearch DesignArthritis, PsoriaticArthritis, RheumatoidBiomedical ResearchCentral Nervous System SensitizationCongresses as TopicHumansLupus Erythematosus, SystemicMolecular Targeted TherapyNeeds AssessmentResearchRheumatic DiseasesRheumatologySpondylitis, Ankylosingankylosing spondylitisinflammatory myopathiespsoriatic arthritisrheumatoid arthritisSjögren’s syndromespondyloarthritissystemic lupus erythematosussystemic sclerosisvasculitis

Identifiers

PMID31662322
PMCPMC6937409

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.